LONG TERM EFFICACY OF INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE AT A SINGLE TERTIARY CENTER

被引：0
|
作者：
Nuti, F. [1 ]
Conte, F. [1 ]
Cavallari, N. [1 ]
Civitelli, F. [1 ]
Aloi, M. [1 ]
Del Giudice, E. [1 ]
Pannone, V. [1 ]
Di Nardo, G. [1 ]
Cucchiara, S. [1 ]
Viola, F. [1 ]
机构：
[1] Univ Roma La Sapienza, Pediat Gastroenterol & Liver Unit, Rome, Italy
来源：
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION | 2010年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E108 / E108
页数：1
相关论文
共 50 条
  • [21] Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
    Fidder, H.
    Schnitzler, F.
    Ferrante, M.
    Noman, M.
    Katsanos, K.
    Segaert, S.
    Henckaerts, L.
    Van Assche, G.
    Vermeire, S.
    Rutgeerts, P.
    GUT, 2009, 58 (04) : 501 - 508
  • [22] Long-term scheduled therapy with infliximab in inflammatory bowel disease: a single-centre observational study
    Felice, C.
    Ferraro, P. M.
    Marzo, M.
    Pugliese, D.
    Papa, A.
    Rapaccini, G. L.
    Guidi, L.
    Armuzzi, A.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S384 - S384
  • [23] Outcome of Biological Therapy in Pediatric Inflammatory Bowel Disease at a Single Tertiary Center
    Nuti, Federica
    Alessandri, Claudia
    Conte, Francesca
    Civitelli, Fortunata
    Aloi, Marina
    Del Giudice, Emanuela
    Dilillo, Anna
    Oliva, Salvatore
    Viola, Franca
    Cucchiara, Salvatore
    GASTROENTEROLOGY, 2011, 140 (05) : S510 - S510
  • [24] Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
    Zabrowski, Douglas
    Abraham, Danielle
    Rosenthal, Geoffrey
    Kader, Howard
    JGH OPEN, 2020, 4 (04): : 636 - 641
  • [25] Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues
    Caviglia, Renato
    Boskoski, Ivo
    Cicala, Michele
    EXPERT OPINION ON DRUG SAFETY, 2008, 7 (05) : 617 - 632
  • [26] Long-Term Safety of Infliximab in CVID-Related Inflammatory Bowel Disease
    Verma, N.
    Webster, A. D.
    Seneviratne, S. L.
    Burns, S. O.
    Dziadio, M.
    Symes, A.
    Workman, S.
    Grimbacher, B.
    Chee, R.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S166 - S167
  • [27] Long-term treatment of inflammatory bowel disease associated spondyloarthropathy with infliximab.
    Antivalle, Marco
    Mutti, Alessandra
    Bertani, Luca
    Randisi, Giovanna
    Vulpio, Laura
    Ardizzone, Sandro
    Colombo, Elisabetta
    Carrabba, Mario
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S472 - S472
  • [28] Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in a Large Tertiary Medical Center
    Wice, Mitchell
    Oppenheim, Shannon
    Miller, Hannah
    Wasan, Sharmeel
    Noronha, Ansu
    Rybin, Denis
    Weinberg, Janice
    Farraye, Francis A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S270 - S270
  • [29] Long term efficacy of azathioprine monotherapy in patients with Inflammatory Bowel Disease
    Theodoraki, E.
    Papatzelou, I.
    Koutroubakis, I.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1444 - I1444
  • [30] Long-Term Use of Purine Analogues in Inflammatory Bowel Disease: A Single Referral Center Experience
    Issa, Mazen
    Zadvomova, Yelena
    Stein, Daniel J.
    Venu, Nanda
    Perera, Lilani P.
    Binion, David G.
    Naik, Amar S.
    GASTROENTEROLOGY, 2011, 140 (05) : S789 - S789
12345